| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
230,290,000 |
| Market
Cap: |
138.17(K) |
| Last
Volume: |
11,847,187 |
Avg
Vol: |
11,814,278 |
| 52
Week Range: |
$0.0001 - $0.066 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Endo International is a holding company. Through its subsidiaries, Co. is engaged in specialty pharmaceuticals. Co.'s segments are: Branded Pharmaceuticals, which includes branded products to treat and manage conditions in the areas of urology, orthopedics, endocrinology and bariatrics, among others; Sterile Injectables, which consists of branded sterile injectable products; Generic Pharmaceuticals, which includes generic product families that treat and manage a range of medical conditions; and International Pharmaceuticals, which includes products serving therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, oncology and transplantation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rudio Daniel |
Vice President, Controller |
• – – |
2014-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
802 |
802 |
|
- |
|
| Farhat Camille |
President, AMS, Inc. |
• – – |
2014-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,416 |
21,394 |
|
- |
|
| Farhat Camille |
President, AMS, Inc. |
• – – |
2014-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,832 |
18,128 |
|
- |
|
| Degolyer Donald W |
Chief Operating Officer,Pharma |
• – – |
2014-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,121 |
35,725 |
|
- |
|
| Degolyer Donald W |
Chief Operating Officer,Pharma |
• – – |
2014-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,242 |
40,846 |
|
- |
|
| Gergel Ivan |
EVP, R&D and CSO |
• – – |
2014-02-23 |
4 |
D |
$77.26 |
$117,203 |
D/D |
(1,517) |
15,695 |
|
- |
|
| Manogue Caroline B |
Exec. V.P., CLO & Secy |
• – – |
2014-02-23 |
4 |
D |
$77.26 |
$115,504 |
D/D |
(1,495) |
55,802 |
|
- |
|
| Rudio Daniel |
Vice President, Controller |
• – – |
2014-02-23 |
4 |
D |
$77.26 |
$10,198 |
D/D |
(132) |
1,653 |
|
- |
|
| Gergel Ivan |
EVP, R&D and CSO |
• – – |
2014-02-22 |
4 |
D |
$77.26 |
$118,285 |
D/D |
(1,531) |
13,883 |
|
- |
|
| Manogue Caroline B |
Exec. V.P., CLO & Secy |
• – – |
2014-02-22 |
4 |
D |
$77.26 |
$127,711 |
D/D |
(1,653) |
54,364 |
|
- |
|
| Rudio Daniel |
Vice President, Controller |
• – – |
2014-02-22 |
4 |
D |
$77.26 |
$14,911 |
D/D |
(193) |
1,463 |
|
- |
|
| Manogue Caroline B |
Exec. V.P., CLO & Secy |
• – – |
2014-02-19 |
4 |
D |
$75.22 |
$500,664 |
D/D |
(6,656) |
52,775 |
|
- |
|
| Gergel Ivan |
EVP, R&D and CSO |
• – – |
2014-02-19 |
4 |
D |
$75.22 |
$761,753 |
D/D |
(10,127) |
12,054 |
|
- |
|
| Rudio Daniel |
Vice President, Controller |
• – – |
2014-02-19 |
4 |
D |
$75.22 |
$15,571 |
D/D |
(207) |
1,208 |
|
- |
|
| Nash David |
Director |
– • – |
2013-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
222 |
11,859 |
|
- |
|
| De Silva Rajiv |
President & CEO |
• • – |
2013-12-31 |
4 |
D |
$67.29 |
$483,075 |
D/D |
(7,179) |
164,921 |
|
- |
|
| Kimmel Roger H |
Director |
– • – |
2013-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
778 |
53,847 |
|
- |
|
| Higgins Arthur J |
Director |
– • – |
2013-12-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,016 |
|
- |
|
| Kimmel Roger H |
Director |
– • – |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,155 |
53,069 |
|
- |
|
| Nash David |
Director |
– • – |
2013-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
330 |
11,637 |
|
- |
|
| Upadhyay Suketu |
EVP, Chief Financial OfficerOf |
• – – |
2013-09-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,418 |
|
- |
|
| Farhat Camille |
President, AMS, Inc. |
• – – |
2013-09-05 |
4 |
D |
$43.00 |
$76,927 |
D/D |
(1,789) |
3,538 |
|
- |
|
| Kimmel Roger H |
Director |
– • – |
2013-08-08 |
4 |
B |
$36.50 |
$199,947 |
D/D |
5,478 |
51,914 |
2.39 |
- |
|
| Hyatt Michael |
Director |
– • – |
2013-08-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
223,853 |
|
- |
|
| Degolyer Donald W |
Chief Operating Officer,Pharma |
• – – |
2013-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,604 |
|
- |
|
825 Records found
|
|
Page 3 of 33 |
|
|
